Gilead reports positive Phase 3 HIV results while Merck's Trodelvy fails in lung cancer trial

Gilead Sciences announced that its Phase 3 HIV trial met its primary efficacy endpoint, delivering a positive readout for the experimental therapy.

In a separate study, Merck reported that its Phase 3 trial of Trodelvy in lung cancer did not achieve the predefined primary endpoint, marking a setback for the oncology program.

Investors had been expecting mixed signals from the two companies, and the favorable HIV data from Gilead is expected to help balance market reaction to Merck's lung cancer miss.

The divergent outcomes highlight the variable risk profile of late‑stage drug development across therapeutic areas.